Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions

Phase 4

Completed

• Conditions: Breast Cancer; Multiple Myeloma; Prostate Cancer

• Registration Number: NCT00029224
• Lead Sponsor: Novartis

Brief Summary

Patients with bone metastases or bone lesions caused by breast cancer, multiple myeloma or prostate cancer will be treated with IV Zometa in a 15 minute infusion. Pain will be evaluated, as well as time in chair, quality of life and safety of Zometa.

Detailed Description

Not available

Study Timeline

• Study Start: 2001-10
• Study First Submitted: 2002-01-09
• Study First Submitted QC: 2002-01-09
• Study First Posted: 2002-01-10
• Primary Completion: 2002-11
• Study Completion: 2002-11
• Status Verified: 2012-01
• Last Update Submitted: 2012-01-30
• Last Update Posted: 2012-02-01

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 500

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Pain score assessed by change from baseline

Secondary Outcome Measures

Name	Time	Method
Quality of life
Time in infusion chair
Safety assessed by adverse events (AEs)

Trial Locations

Locations (7)

Stockton Hematology Oncology Medical Group; 🇺🇸 Stockton, California, United States

Osceola Cancer Center; 🇺🇸 Kissimmee, Florida, United States

Nevada Cancer Center; 🇺🇸 Las Vegas, Nevada, United States

Hematology-Oncology Associates PC; 🇺🇸 Albuquerque, New Mexico, United States

New Mexico Oncology Hematology Consultants; 🇺🇸 Albuquerque, New Mexico, United States

Hematology Oncology Associates, PC; 🇺🇸 Medforo, Oregon, United States

Virginia Physicians, Inc; 🇺🇸 Richmond, Virginia, United States